BioAtla, Inc.
BCAB · OTCMCIK 1826892fmd_1FS96JG7DFTM8KW1SSGZ805KHHManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2019 to Jun 30, 2026, 27 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | – | – | 0 | – | – | – | – |
| Research and development | 26 | 20 | 58 | 79 | 104 | 63 | 44 |
| Total operating expenses | 33 | 31 | 97 | 108 | 130 | 85 | 61 |
| Operating income | (28) | (30) | (96) | (108) | (130) | (74) | (59) |
| Interest expense | 2 | 1 | 0 | 0 | – | – | – |
| Interest and investment income | 0 | 0 | 0 | 2 | 6 | 3 | 1 |
| Other non-operating income (expense) | (2) | (6) | 1 | 2 | 6 | 4 | (0) |
| Income tax expense | – | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | (30) | (36) | (95) | (106) | (123) | (70) | (60) |